Menu
Search Close

News

Final Results for the year ended 30 April 2010

14th July 2010

Scancell Holdings plc, (PLUS:SCLP), the developer of therapeutic cancer vaccines, announces its final results for the year ended 30 April 2010.

Highlights:

  • Strong progress in the development of the Company’s lead therapeutic melanoma vaccine SCIB1
  • Successful fundraising of £2.54 million (gross) during 2010
  • Loss before tax for the year of £1.80 million (2009: £0.8 million)
  • Cash at year end of £2.83 million
  • Since the year end the Company commenced Phase I/IIa clinical trials in humans for SCIB1

The Directors of the issuer accept responsibility for this announcement.

For further information contact:

Professor Lindy Durrant, (CEO)  -  Scancell Holdings Plc:

  • +44 (0)207 245 1100

John Bick/Kirsty Corcoran  -  Hansard Communications

  • +44 (0)207 245 1100
  • +44 (0)7872 061 007

Ross Andrews/Tom Rowley  -  Zeus Capital

  • +44 (0)161 831 1512

View the full document

Webcasts, Interviews and Media Coverage

Vulpes Life Sciences Fund's Martin Diggle discusses Scancell investment

Martin Diggle, co-founder of Vulpes Investment Management which manages the Vulpes Life Sciences Fund, discusses their recent investment into Scancell Holdings PLC (LON:SCLP).

After buying 77.56mln new shares at a price of 5p per share, which was a slight discount to the 5.35p closing price the previous day, the Vulpes Life Sciences Fund will have a 16.67% stake in the company.

Fri, 21 Jun 2019 08:21:00

Scancell welcomes strategic new investor Vulpes Life Sciences Fund

Scancell Holdings PLC (LON:SCLP) CEO Cliff Holloway caught up with Proactive London's Andrew Scott following the announcement they'd raised £3.88mln via a placing with a single new investor to help fund the progression of its lead cancer asset into clinical trials.

The Vulpes Life Sciences Fund will now have a 16.67% stake in the company when the shares are issued next Monday.

Thu, 13 Jun 2019 09:53:00

Scancell raises £3.9mln to advance immunotherapy product pipeline

“At Vulpes we are always searching for overlooked companies that have the ability to make significant advances in medical science, with a view to supporting their development over the long term. We believe Scancell fulfil these criteria perfectly.”

Thu, 13 Jun 2019 06:31:00